The Oncotype DX Recurrence Score's Impact on the Management of Oestrogen-Positive/Human Epidermal Growth Factor Receptor 2-Negative, Low-Burden Axillary Status Breast Cancer (REHAB Study): Results of a Single Centre

Background The Oncotype DX Recurrence Score (ODX-RS) is increasingly utilized in oestrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative, low-burden axillary disease early operable breast cancer. It has been demonstrated to predict the benefits of adjuvant chemother...

Descripción completa

Detalles Bibliográficos
Autores principales: Saad Abdalla Al-Zawi, Abdalla, Yin, Su-Lei, Mahmood, Bayan, Jalil, Awais, Aladili, Zina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Genetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411820/
https://www.ncbi.nlm.nih.gov/pubmed/36042999
http://dx.doi.org/10.7759/cureus.27341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411820/
https://www.ncbi.nlm.nih.gov/pubmed/36042999
http://dx.doi.org/10.7759/cureus.27341

Ejemplares similares